Preventing distal particles embolization after DCB angioplasty

At EuroPCR 2025, Aloke Finn and Antonio Colombo share their insights on a specific and often overlooked complication of drug-coated balloon (DCB) angioplasty: particulate embolization.

They begin by clarifying the distinction between this phenomenon and traditional distal embolization, explaining that particulate embolization is iatrogenic and device-related—it is not due to plaque or thrombus, but rather to the release of particles from the balloon coating itself.

Is this clinically significant for patients? The answer depends on the drug and the excipient used: some DCBs with smaller carriers tend to release fewer particles and have a lower impact on downstream organ function. The discussion touches on the variability among devices and how certain technologies may reduce the risk.

The conversation then shifts to the translation of preclinical data into clinical awareness: how can clinicians recognize and manage the potential consequences of particulate embolization? How should we adapt clinical practice? And what innovations could make DCBs even safer in the future?

The message is clear: particulate embolization is not universal, not always clinically relevant—but it does exist. And for some patients, it matters.

Learn how to identify, prevent, and manage this risk in your practice.

This interview was filmed at EuroPCR 2025: see more videos here.